Medicxi Ventures Management (Jersey) Ltd NAMS — NEWAMSTERDAM PHARMA COMPANY

Ownership history in Medicxi Ventures Management (Jersey) Ltd  ·  15 quarters on record

AI Ownership Summary

Medicxi Ventures Management (Jersey) Ltd reported NEWAMSTERDAM PHARMA COMPANY (NAMS) in 15 quarterly 13F filings from 2024 Q1 through 2026 Q2. Peak portfolio weight reached 42.19% in 2026 Q2. The latest visible filing shows NAMS at 42.19% of the fund.

This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings. Older history is available after unlock; the visible window still shows the most recent pattern.

What this NAMS ownership page tells you

This page is designed to answer the real investor question behind a 13F filing: how meaningful was Medicxi Ventures Management (Jersey) Ltd's position in NEWAMSTERDAM PHARMA COMPANY, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.

Freshest filing
Latest Reported Filing
2026 Q2

NAMS was reported at 42.19% of portfolio in the most recent visible filing.

High-water mark
Peak Conviction
42.19% in 2026 Q2

Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.

Time in book
Holding Window
2024 Q1 to 2026 Q2

Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.

Decision context
Why It Matters
Position size beats headlines

Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.

NAMS stock page Medicxi Ventures Management (Jersey) Ltd fund profile Medicxi Ventures Management (Jersey) Ltd full holdings
How Medicxi Ventures Management (Jersey) Ltd held NAMS — position size vs. price
% of Fund (quarterly)    NAMS price (quarter-end, indexed to 100)    SPY (indexed to 100)    QQQ (indexed to 100)
📋 Quarterly Holdings History 10 quarters  ▾
Quarter Action Sold % After 3M Timing Shares Change Chg % % of Fund Mkt Value Filed Price (Filed)
2026 Q2 REDUCED — — — 2,208,639 -465,543 -17.4% 42.19% $74.9M 2026-08-04 $27.55
2026 Q1 REDUCED 6.8% +5.8% ❌ 2,674,182 -195,383 -6.8% 8.72% $85.6M 2026-04-21 $32.48
2025 Q4 UNCHANGED — — — 2,869,565 — 0% 12.06% $100.7M 2026-01-23 $33.32
2025 Q3 UNCHANGED — — — 2,869,565 — 0% 10.96% $81.6M 2025-10-17 $36.40
2025 Q2 UNCHANGED — — — 2,869,565 — 0% 12.16% $52.0M 2025-07-08 $20.02
2025 Q1 UNCHANGED — — — 2,869,565 — 0% 13.42% $58.7M 2025-04-11 $15.12
2024 Q4 UNCHANGED — — — 2,869,565 — 0% 13.94% $73.7M 2025-01-23 $23.20
2024 Q3 UNCHANGED — — — 2,869,565 — 0% 9.01% $47.6M 2024-10-15 $19.00
2024 Q2 UNCHANGED — — — 2,869,565 — 0% 16.44% $55.1M 2024-07-16 $19.29
2024 Q1 UNCHANGED — — — 2,869,565 — 0% 15.11% $67.9M 2024-04-15 $19.74
5 older quarters hidden  —  Sign in free or upgrade to Premium to see full history

🏢 Other funds also holding NAMS

As of 2026 Q2 — sorted by position size

FCPM III SERVICES B.V. 38.34% Frazier Life Sciences Management, L.P. 3Y 13.35% Bain Capital Life Sciences Investors, LLC 3Y 7Y 7.67% Artia Global Partners LP 3Y 3.15% RA CAPITAL MANAGEMENT, L.P. 3Y 7Y 2.81% Atle Fund Management AB 3Y 7Y 2.27% First Turn Management, LLC 2.11% Duquesne Family Office LLC 3Y 7Y 2.0% DEERFIELD MANAGEMENT COMPANY, L.P. 3Y 7Y 1.51% NWI MANAGEMENT LP 3Y 7Y 1.1%

FAQ About Medicxi Ventures Management (Jersey) Ltd and NAMS

These are the practical questions this page is built to answer before you even open the full history table.

How long has Medicxi Ventures Management (Jersey) Ltd reported owning NAMS?

Medicxi Ventures Management (Jersey) Ltd reported NAMS across 10 quarterly 13F filings, from 2024 Q1 through 2026 Q2.

What was the largest reported NAMS position in Medicxi Ventures Management (Jersey) Ltd's portfolio?

The largest reported portfolio weight for NAMS was 42.19% in 2026 Q2.

What is the latest reported NAMS position on this page?

The most recent filing on this page is 2026 Q2, when Medicxi Ventures Management (Jersey) Ltd reported 2,208,639 shares, equal to 42.19% of portfolio, with an estimated market value of $74.9M.

What does the chart on this NAMS ownership page compare?

The chart compares Medicxi Ventures Management (Jersey) Ltd's quarterly NAMS portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.

How well did Medicxi Ventures Management (Jersey) Ltd time their NAMS position?

Based on 13F filing dates vs. subsequent NAMS price moves, Medicxi Ventures Management (Jersey) Ltd correctly timed 2 out of 3 reported position changes (67%). The annualised alpha on NAMS relative to SPY over the holding period was +1.1%.

← Back to Medicxi Ventures Management (Jersey) Ltd Holdings